Japanese Medical Startups to Generate Clinical Evidence in the US with JETRO Support

Five pioneering medical startups from Japan are set to create clinical evidence in the United States, a strategic move that could enhance their market presence. Supported by the Japan External Trade Organization (JETRO), these companies are focusing on FDA approval and insurance reimbursement, which are crucial for success in the competitive US healthcare landscape. This development is significant for foreign entrepreneurs, highlighting growing collaboration between Japanese startups and US regulatory frameworks, offering insights into navigating similar pathways in Japan.

Background & Context

The Japanese healthcare startup ecosystem is gaining momentum, particularly in medical technology and pharmaceuticals. The Japan External Trade Organization (JETRO) plays a pivotal role in supporting these startups by providing resources and guidance for international expansion. The regulatory framework in Japan is governed by the Pharmaceuticals and Medical Devices Act (PMD Act), which outlines the approval process for medical devices and pharmaceuticals. Recently, the focus has shifted towards aligning with international standards, particularly those set by the US Food and Drug Administration (FDA). This alignment is essential for Japanese startups aiming to enter the US market, facilitating smoother entry and enhancing credibility. The timeline of regulatory changes has seen Japan increasingly adopting practices favorable for startups, including expedited approval processes and support for clinical trials. JETRO’s initiative to assist five medical startups in creating clinical evidence in the US marks a significant step in this direction, emphasizing the importance of FDA approval and insurance reimbursement as critical milestones for success.

How This Affects Your Business in Japan

Item	Cost (JPY)	Cost (USD approx)	Notes
Company Registration	¥150,000	$1,050	Standard registration fee
Notary Fee	¥50,000	$350	For document notarization
Visa Application	¥4,000	$28	Business Manager Visa

1. Foreign Residents Already Operating a Business in Japan
For those already in the Japanese market, this development offers a roadmap for expanding into the US. Collaborating with JETRO can provide insights into the FDA approval process and necessary documentation. Key actions include conducting market research, identifying potential partners in the US, and initiating clinical trials. Delays in addressing these areas could result in missed opportunities in the lucrative US healthcare market.

2. Foreign Nationals Planning to Establish a New Company
New entrepreneurs should leverage the support available from JETRO. They can benefit from guidance on regulatory compliance and market entry strategies. Developing a robust business plan that prioritizes FDA approval is advisable. Engaging with clinical research organizations (CROs) in the US to facilitate trials is crucial. Failure to do so may hinder their ability to compete effectively in the US market.

3. Foreign Investors Who Are NOT Residents of Japan
Investors looking to fund Japanese medical startups should assess the potential for FDA-approved products. Seeking detailed business plans from startups that outline their FDA strategy and reimbursement pathways is essential. Engaging with JETRO can provide insights into the viability of investments in these startups. Not acting on this information could lead to investing in companies that may struggle to gain market access in the US.

Step-by-Step: What You Need to Do

Step 1: Research the FDA Approval Process
Start by understanding the FDA’s requirements for medical devices or pharmaceuticals. Contact the FDA or consult with a regulatory expert. English support is available.
Office: FDA (English Support: Yes)
Cost: Free (¥0)
Time: 1-2 weeks
Pitfall: Overlooking specific FDA requirements

Step 2: Engage with JETRO
Reach out to JETRO for assistance in navigating the US market and understanding reimbursement policies. English support is available.
Office: JETRO (English Support: Yes)
Cost: Free (¥0)
Time: Ongoing
Pitfall: Not utilizing available resources

Step 3: Conduct Clinical Trials
Partner with a CRO in the US to design and implement clinical trials. Contact potential CROs directly. English support is available.
Office: Various CROs (English Support: Yes)
Cost: ¥10,000,000-¥30,000,000 (~$70,000-$210,000 USD)
Time: 6-12 months
Pitfall: Inadequate trial design

Step 4: Prepare Documentation for FDA Submission
Compile all necessary documentation for FDA submission, including clinical trial results and product information. Consult with a regulatory affairs consultant if needed. English support is available.
Office: Regulatory Affairs Consultants (English Support: Yes)
Cost: ¥1,000,000-¥5,000,000 (~$7,000-$35,000 USD)
Time: 3-6 months
Pitfall: Incomplete documentation

Step 5: Submit FDA Application
Submit your application to the FDA and respond to any queries. Contact the FDA for guidance. English support is available.
Office: FDA (English Support: Yes)
Cost: ¥500,000-¥1,500,000 (~$3,500-$10,500 USD)
Time: 6-12 months
Pitfall: Delayed responses to FDA queries

Step 6: Plan for Insurance Reimbursement
Research and apply for insurance reimbursement options in the US. Contact insurance companies directly. English support is available.
Office: Insurance Companies (English Support: Limited)
Cost: Varies based on the insurance provider
Time: 3-6 months
Pitfall: Misunderstanding reimbursement criteria

Key Contacts
www.jetro.go.jp/en/
www.moj.go.jp/isa/
www.fda.gov

Expert Analysis: Japan vs. Regional Competitors

Metric	Japan	Singapore	Hong Kong	South Korea
Incorporation Time	14 days	3 days	5 days	10 days
Minimum Capital Requirement	¥0	S$1	HK$1	₩1
Corporate Tax Rate	30%	17%	16.5%	22%
Visa Processing Time	1 month	2 weeks	3 weeks	1 month

What to Expect Next

Looking ahead, further developments in Japan’s regulatory landscape are expected to enhance support for medical startups. Key legislation related to the Pharmaceuticals and Medical Devices Act (PMD Act) is likely to evolve, focusing on expedited approval processes and increased collaboration with international regulatory bodies. Entrepreneurs should monitor announcements from JETRO and the Ministry of Health, Labour and Welfare (MHLW) for updates on new policies and initiatives. The next 12-24 months will be crucial for observing how these changes impact the ability of Japanese startups to thrive in the US market.

---

Sources & References

This article is based on the following source and enhanced with professional analysis for foreign business owners.
Source: 日本発医療スタートアップ5社、米国で臨床エビデンス創出へ ―ジェトロ、FDA承認・保険償還を見据え、研究設計からデータ検証まで一貫支援―

⚠️ This article is for informational purposes only and does not constitute legal advice. Please consult a qualified Japanese attorney (bengoshi) or judicial scrivener (shiho shoshi) for advice specific to your situation.